title: Clinical efficiency of Epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.
abstract: Clinical efficiency and safety of Epigam containing antibodies to histamine in ultralow doses were studied during the therapy of patients with exacerbation of peptic ulcer disease of the stomach and duodenum associated with Helicobacter pylori infection. We examined 20 patients (18-50 years) with ulcerative lesions of the mucosal layer in the stomach and duodenum and H. pylori infection. Epigam (1 tablet, 6 times a day) or H2 receptor blocker ranitidine (150 mg, 2 times a day) were given in combination with amoxicillin (500 mg, 3 times a day, 14 days) and metronidazole (500 mg, 2 times a day, 14 days) for 28 days. The efficiency of treatment was determined before and 1, 2, 3, and 4 weeks after the start of therapy. The symptoms of peptic ulcer disease and time of ulcer healing underwent similar changes in patients of both groups. However, after ranitidine therapy pain syndrome disappeared more rapidly than in patients receiving Epigam. Epigam did not cause undesirable side effects. Our results indicate that Epigam is an efficient and safe preparation that may be used for combination therapy of patients with peptic ulcer disease of the stomach and duodenum.
authors.affiliation: Volgograd Medical Academy.
authors.forename: P A
authors.initials: PA
authors.lastname: Bakumov
authors.forename: I V
authors.initials: IV
authors.lastname: Shchepotkin
authors.forename: Yu L
authors.initials: YL
authors.lastname: Dugina
authors.forename: O I
authors.initials: OI
authors.lastname: Epstein
authors.forename: S A
authors.initials: SA
authors.lastname: Sergeeva
mesh_terms: D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D000906:Antibodies / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004386:Duodenum / Q000187:drug effects / Q000473:pathology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy; D006632:Histamine / Q000276:immunology; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D011899:Ranitidine / Q000627:therapeutic use; D013270:Stomach / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000897:Anti-Ulcer Agents; D000906:Antibodies; D008795:Metronidazole; D000658:Amoxicillin; D006632:Histamine; D011899:Ranitidine